RNA Origami Nanostructures for Potent and Safe Anticancer Immunotherapy

Xiaodong Qi, Xiaowei Liu, Lawrence Matiski, Ryan Rodriguez Del Villar, Theresa Yip, Fei Zhang, Sriram Sokalingam, Shuoxing Jiang, Li Liu, Hao Yan, Yung Chang

Research output: Contribution to journalArticlepeer-review

46 Scopus citations

Abstract

Rapid developments in nucleic acid nanotechnology have enabled the rational design and construction of self-assembling DNA and RNA nanostructures that are highly programmable. We recently developed a replicable single-stranded RNA origami (RNA-OG) technology that allows a long RNA molecule to be programmed to self-assemble into nanostructures of various shapes. Here, we show that such RNA-OG is highly stable in serum/plasma, and we thus exploited its immunostimulatory potential. We demonstrated that the RNA-OG stimulates a potent innate response primarily through a Toll-like receptor 3 (TLR3) pathway. In a murine peritoneal metastatic colon cancer model, intraperitoneally injected RNA-OG induced significant tumor retardation or regression by activating NK- and CD8-dependent antitumor immunity and antagonizing the peritoneal immunosuppressive environment. Unlike polyinosinic/polycytidylic acid (PolyIC), a well-known double-stranded RNA analogue, the RNA-OG treatment did not cause a high level of type-I interferons in the blood nor apparent toxicity upon its systemic administration in the animals. This work establishes the function of RNA-OG as a potent line of TLR3 agonists that are safe and effective for cancer immunotherapy.

Original languageEnglish (US)
Pages (from-to)4727-4740
Number of pages14
JournalACS nano
Volume14
Issue number4
DOIs
StatePublished - Apr 28 2020

Keywords

  • RNA nanostructures
  • RNA origami
  • TLR3 agonists
  • cancer immunotherapy
  • peritoneal metastatic colon cancer

ASJC Scopus subject areas

  • General Materials Science
  • General Engineering
  • General Physics and Astronomy

Fingerprint

Dive into the research topics of 'RNA Origami Nanostructures for Potent and Safe Anticancer Immunotherapy'. Together they form a unique fingerprint.

Cite this